Kizzmekia S Corbett,Barbara Flynn,Kathryn E Foulds,Joseph R Francica,Seyhan Boyoglu-Barnum,Anne P Werner,Britta Flach,Sarah O'Connell,Kevin W Bock,Mahnaz Minai,Bianca M Nagata,Hanne Andersen,David R Martinez,Amy T Noe,Naomi Douek,Mitzi M Donaldson,Nadesh N Nji,Gabriela S Alvarado,Darin K Edwards,Dillon R Flebbe,Evan Lamb,Nicole A Doria-Rose,Bob C Lin,Mark K Louder,Sijy O'Dell,Stephen D Schmidt,Emily Phung,Lauren A Chang,Christina Yap,John-Paul M Todd,Laurent Pessaint,Alex Van Ry,Shanai Browne,Jack Greenhouse,Tammy Putman-Taylor,Amanda Strasbaugh,Tracey-Ann Campbell,Anthony Cook,Alan Dodson,Katelyn Steingrebe,Wei Shi,Yi Zhang,Olubukola M Abiona,Lingshu Wang,Amarendra Pegu,Eun Sung Yang,Kwanyee Leung,Tongqing Zhou,I-Ting Teng,Alicia Widge,Ingelise Gordon,Laura Novik,Rebecca A Gillespie,Rebecca J Loomis,Juan I Moliva,Guillaume Stewart-Jones,Sunny Himansu,Wing-Pui Kong,Martha C Nason,Kaitlyn M Morabito,Tracy J Ruckwardt,Julie E Ledgerwood,Martin R Gaudinski,Peter D Kwong,John R Mascola,Andrea Carfi,Mark G Lewis,Ralph S Baric,Adrian McDermott,Ian N Moore,Nancy J Sullivan,Mario Roederer,Robert A Seder,Barney S Graham

Abstract:Background: Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. Methods: Nonhuman primates received 10 or 100 μg of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2. Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens. Results: The mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID50) geometric mean titers of 501 in the 10-μg dose group and 3481 in the 100-μg dose group. Vaccination induced type 1 helper T-cell (Th1)-biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses. Viral replication was not detectable in BAL fluid by day 2 after challenge in seven of eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of the eight animals in the 100-μg dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group. Conclusions: Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.).

Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates

Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants

A Recombinant Receptor-Binding Domain in Trimeric Form Generates Protective Immunity Against SARS-CoV-2 Infection in Nonhuman Primates

Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice

Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates

A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates

Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates

Protection Against SARS-CoV-2 Infection by a Mucosal Vaccine in Rhesus Macaques.

Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques

A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates

Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine

An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates